Infantile Spasms

1. Disease Information

Overview. Infantile spasms (IS) is an age-specific epileptic encephalopathy of infancy classically defined by a triad of (1) epileptic/infantile spasms, (2) a characteristic chaotic interictal EEG pattern called hypsarrhythmia, and (3) developmental arrest or regression. When all three are present the condition has historically been called West syndrome, first described by William James West in 1841 in his own son. The 2022 ILAE nosology renamed and broadened the entity to Infantile Epileptic Spasms Syndrome (IESS), which requires epileptic spasms but does not require hypsarrhythmia, recognizing that spasms and developmental impairment can occur with atypical or absent hypsarrhythmia (According to PubMed — Zuberi et al., Epilepsia 2022, PMID 35503712, DOI; Pavone et al., Neurol Sci 2020, PMID 32827285, DOI).

The 2020 comprehensive review states the classical definition directly: "the classical triad of (1) infantile spasms; (2) hypsarrhythmia, and (3) developmental arrest or regression as 'West syndrome'" and notes it is "currently regarded as a spectrum of disorders: the so-called infantile spasm syndrome (ISs), in association with other causal factors, including structural, infectious, metabolic, syndromic, and immunologic events, all acting on a genetic predisposing background" (PMID 32827285, DOI).

Key identifiers. - MONDO: MONDO:0018097 (infantile spasms / West syndrome) — verified via OLS. - HPO (phenotype): HP:0012469 Infantile spasms; HP:0011097 Epileptic spasm. - OMIM: No single OMIM number for the syndrome overall; genetically defined forms use "Developmental and epileptic encephalopathy" (DEE) series entries. The X-linked ARX-related form maps to OMIM 308350 (EIEE1/DEE1); many others in the DEE series (e.g., CDKL5, STXBP1, SPTAN1). - ICD-10: G40.4 (other generalized epilepsy and epileptic syndromes; West syndrome). ICD-11: 8A62 (Infantile epileptic spasms syndrome / epileptic spasms). - MeSH: D013036 "Spasms, Infantile" (UMLS CUI C0037769, "West syndrome"). - Orphanet: ORPHA:3451 (West syndrome). - NBO: NBO:0000734 infantile spasm.

Data derivation. Aggregate disease-level resources (OMIM, Orphanet, ILAE syndrome definitions) plus multicenter prospective cohorts (National Infantile Spasms Consortium; ICISS trial). Individual-patient/EHR-derived data exist chiefly through registries and consortium cohorts rather than routine EHR mining.

Synonyms: West syndrome; infantile spasms; epileptic spasms; infantile epileptic spasms syndrome (IESS, the current ILAE term); "salaam attacks/seizures" (historical, from the flexor posture); jackknife/flexion spasms; generalized flexion epilepsy (historical, Gibbs). Note the ILAE distinction: infantile spasms denotes onset <1 year in the classic window; epileptic spasms is the seizure semiology term, which can occur beyond infancy.

2. Etiology

IESS is etiologically heterogeneous — a final common phenotype reached by many upstream insults acting on the developing brain during a critical window (typically 3–12 months). The most useful etiologic framework is the ILAE structural/genetic/metabolic/infectious/immune/unknown scheme.

Distribution of causes. The 2024 genetics review summarizes: "broadly, 60% of cases are thought to be structural, metabolic or infectious in nature, with the remainder genetic or of unknown cause" (Snyder et al., Genes 2024, PMID 38540325, DOI). Historically ~60–70% are "symptomatic" (identifiable cause) and ~30–40% "cryptogenic/unknown," though modern genetic testing steadily shrinks the unknown fraction.

Structural causes: - Tuberous sclerosis complex (TSC) — the single most recognizable cause (~10–25% of symptomatic IS). TSC affects "approximately 1 per 6000–10,000 individuals" and "the pediatric neurologist is often responsible for making the initial diagnosis when the affected individual presents with infantile spasms or another early-onset epilepsy syndrome" (Islam, Semin Pediatr Neurol 2021, PMID 33892851, DOI). - Malformations of cortical development — focal cortical dysplasia (FCD type II), hemimegalencephaly, lissencephaly, polymicrogyria. In a surgical IESS cohort, "a genetic diagnosis was achieved in 47 children (80% of cohort)," with germline variants in 46% and brain somatic (mosaic) variants in 36%, and mTOR-pathway/SLC35A2-related MOGHE being major causes (Coleman et al., Brain Commun 2025, PMID 39926610, DOI). - Hypoxic-ischemic encephalopathy (HIE), perinatal stroke, periventricular leukomalacia, intracranial hemorrhage, CNS infection sequelae, trauma.

Metabolic causes: pyridoxine (vitamin B6)-dependent epilepsy (ALDH7A1), pyridoxal-5′-phosphate deficiency (PNPO), biotinidase deficiency, PKU (untreated), mitochondrial disorders, nonketotic hyperglycinemia, Menkes disease, congenital disorders of glycosylation, glucose transporter-1 (GLUT1/SLC2A1) deficiency.

Infectious causes: congenital CMV (most common infectious cause), congenital Zika, rubella, toxoplasmosis, herpes, bacterial meningitis/encephalitis sequelae.

Risk factors: prematurity, perinatal asphyxia, low birth weight, structural brain injury, family history of TSC or a monogenic DEE, chromosomal syndromes (esp. Down syndrome). Male predominance is modest (~55–60% male).

Protective factors: In TSC specifically, preemptive/preventive antiseizure treatment is protective. The EPISTOP trial showed vigabatrin started on the basis of epileptiform EEG (before clinical seizures) "reduced the risk of clinical seizures (OR = 0.21, p = 0.032), drug-resistant epilepsy (OR = 0.23, p = 0.022), and infantile spasms (OR = 0, p < 0.001)" (Kotulska et al., Ann Neurol 2021, PMID 33180985, DOI). No robust dietary/lifestyle protective factors are established for non-TSC IS. There are no well-validated protective germline variants.

Gene–environment interaction. The prevailing model is a genetic predisposing background on which structural/metabolic/infectious insults act (PMID 32827285). Somatic mosaicism (a "genetic" lesion confined to brain arising during development) is itself a gene×developmental-timing interaction, and a "two-hit" germline+somatic mechanism was documented in the surgical cohort (PMID 39926610).

3. Phenotypes

Core seizure phenotype — epileptic/infantile spasms (HP:0011097 / HP:0012469): sudden, brief (0.5–2 s) symmetric contractions, typically flexor, extensor, or mixed flexor-extensor, characteristically occurring in clusters (dozens to hundreds/day), often on awakening. Onset 3–12 months (peak 4–7 months). Frequency: near-universal by definition.

Hypsarrhythmia (EEG sign; ~82% of cohort): The National Infantile Spasms Consortium found "Eighty-two percent of patients had hypsarrhythmia, but this was not associated with gender, mean age, preexisting developmental delay or epilepsy, etiology, or response to first-line therapy" (Demarest et al., Epilepsia 2017, PMID 29105055, DOI). Suggested term: HP:0002521 Hypsarrhythmia.

Developmental impairment / regression (HP:0001263 Global developmental delay; HP:0002376 Developmental regression): developmental arrest or regression (loss of social smile, visual attention, motor milestones) is a defining feature; long-term intellectual disability is frequent.

Associated/downstream phenotypes: - Intellectual disability (HP:0001249) — majority; often moderate-severe. - Autism spectrum features (HP:0000717) — elevated risk, esp. TSC. - Evolution to other epilepsies, notably Lennox-Gastaut syndrome and focal epilepsy (HP:0002123 Generalized myoclonic seizures; HP:0002133 Status epilepticus in some). - Visual inattention/cortical visual impairment (HP:0100704 / HP:0000618). - Microcephaly (HP:0000252) when secondary to structural/genetic cause. - Hypotonia (HP:0001252).

Severity & course: Severe by definition; developmentally the trajectory strongly depends on etiology and lead time to effective treatment (see §8, §11). Cryptogenic/unknown-cause cases with normal pre-onset development and rapid response have the best cognitive outcomes.

Quality-of-life impact: Profound — combined seizure burden plus developmental/behavioral disability imposes very high caregiver burden and lifelong dependency in many. (Disease-specific validated QoL data are limited; ICISS used the Vineland Adaptive Behaviour Scales as the developmental outcome — see §11.)

4. Genetic / Molecular Information

Scale of genetic contribution. "Over 28 copy number variants and 70 single gene pathogenic variants related to IESS have been discovered to date," with commonly reported etiologies including trisomy 21 and single-gene variants (Snyder et al., PMID 38540325, DOI).

Major causal genes (gene symbol / HGNC / mechanism): - TSC1 (HGNC:12362) & TSC2 (HGNC:12363) — loss of function → mTORC1 hyperactivation (mTORopathy). TSC2 more severe. (PMID 33892851) - ARX (HGNC:18060; Xp21.3; OMIM 308350) — X-linked interneuronopathy; polyalanine expansions and LoF; classic monogenic IS model. - CDKL5 (HGNC:11411; X-linked) — DEE with early spasms. - STXBP1 (HGNC:11444) — synaptic vesicle release; haploinsufficiency. - SPTAN1, GRIN1, GRIN2B, SCN1A, SCN2A, SCN8A, KCNQ2, STK39, DNM1, GABRB3, FOXG1, MEF2C, CDKL5, SLC35A2, MTOR, AKT3, PIK3CA, DEPDC5, TSC1/2 (structural/mosaic mTOR pathway). SLC35A2 somatic variants define MOGHE (mild malformation of cortical development with oligodendroglial hyperplasia). - Chromosomal: Trisomy 21 (Down syndrome; strongest chromosomal association), 1p36 deletion, Miller-Dieker (17p13.3, PAFAH1B1/LIS1), 15q duplication, Pallister-Killian.

Variant classes: missense, nonsense, frameshift, splice-site, CNVs/deletions, polyalanine tract expansions (ARX), and brain-restricted somatic mosaic variants (mTOR pathway, SLC35A2). Classification per ACMG/AMP; deposited in ClinVar/DECIPHER.

Somatic vs germline. Landmark finding in surgical IESS: "Germline pathogenic variants were identified in 27/59 (46%)… Pathogenic brain somatic variants were identified in 21/59 (36%)… Somatic mosaicism was a major cause of focal cortical dysplasia type II/hemimegalencephaly (81%) and mild malformation of cortical development with oligodendroglial hyperplasia (100%)" (Coleman et al., PMID 39926610, DOI).

Functional consequences: convergent themes — (i) mTOR pathway hyperactivation (TSC1/2, DEPDC5, MTOR, PIK3CA, AKT3); (ii) GABAergic interneuron dysfunction / interneuronopathy (ARX); (iii) synaptic/ion-channel dysfunction (STXBP1, SCN, KCNQ2, GRIN).

Epigenetics / modifiers: SLC35A2 (glycosylation) and MOGHE illustrate a distinct mechanistic class. Formal modifier-gene and methylation data are limited; the diverse genetic background is itself thought to modify penetrance of structural insults (PMID 32827285).

Diagnostic yield. Trio exome/genome and CMA give the highest yields; up to 80% in structurally-defined surgical cohorts (PMID 39926610), lower (~30–40%) in unselected IS.

5. Environmental Information

• Perinatal/environmental insults: hypoxia-ischemia, prematurity, perinatal stroke, hypoglycemia, kernicterus, trauma, CNS infection.
• Infectious agents: congenital CMV (NCBITaxon:10359) is the leading infectious cause; also congenital Zika virus (NCBITaxon:64320), rubella, Toxoplasma gondii, HSV, and bacterial meningitis sequelae.
• Toxins/lifestyle: No established causal lifestyle exposure. Historically, IS was linked to whole-cell pertussis vaccine, but controlled studies attribute this to coincidental timing (onset window coincides with immunization schedule), not causation. Vitamin B6 (pyridoxine) dependency/deficiency is a treatable metabolic mimic to exclude.

6. Mechanism / Pathophysiology

IS is a developmental-window disorder: diverse insults converge on age-specific network dysfunction during a period of rapid synaptogenesis, myelination, and GABAergic maturation. No single unifying mechanism explains all cases; several complementary models are supported by animal work.

Molecular pathways: - mTOR (mechanistic target of rapamycin) hyperactivation — the best-defined pathway (TSC1/2 → mTORC1 disinhibition). "the identification of the responsible genes and gene products forming the mechanistic target of rapamycin complex… has inspired the search for targeted interventions" (PMID 33892851). Suggested GO: GO:0032008 positive regulation of TOR signaling; GO:0038202 TORC1 signaling. - Stress axis / CRH hypothesis — corticotropin-releasing hormone as an endogenous convulsant in the immature brain, motivating ACTH/steroid efficacy. The CRH model "showed the higher proconvulsant potency of CRH in developing rats" (Galanopoulou, Brain Dev 2013, PMID 23312951, DOI). Proposed mechanism for ACTH: suppression of CRH via negative feedback and melanocortin receptor signaling. GO: GO:0051458 corticotropin secretion. - GABAergic interneuronopathy (ARX) — impaired tangential migration/function of cortical interneurons → excitation–inhibition imbalance. GABA also explains vigabatrin efficacy (irreversible GABA-transaminase inhibitor → ↑GABA). GO: GO:0021853 cerebral cortex GABAergic interneuron migration; CHEBI: GABA CHEBI:16865. - Cortical–subcortical (brainstem) network dysfunction — disruption of cortical–brainstem communication implicated in the spasm generator (PMID 23312951).

Cellular processes / cell types: - Cortical GABAergic interneurons (CL:0000617 GABAergic neuron) — dysfunction/interneuronopathy. - Cortical excitatory pyramidal neurons (CL:0000598 pyramidal neuron). - Dysmorphic neurons / balloon cells in FCD II/TSC tubers (mTOR-driven). - Oligodendroglial hyperplasia in MOGHE (SLC35A2). - Neuroinflammation and abnormal neuronal migration/proliferation contribute (PMID 23312951).

Causal chain (representative, mTOR/structural): genetic or somatic mTOR-activating lesion → abnormal cortical cytoarchitecture (tubers/dysplasia, dysmorphic neurons) → aberrant excitatory–inhibitory network with immature-brain-specific hyperexcitability → epileptic spasms + hypsarrhythmia during the critical developmental window → epileptic encephalopathy disrupting normal development → developmental arrest/regression and later epilepsy (LGS/focal).

Causal chain (stress/CRH model): brain insult → dysregulated CRH/HPA-axis signaling in immature limbic/brainstem circuits → age-specific spasm generation → ACTH/steroid feedback suppresses CRH → clinical response (PMID 23312951).

Anatomical/subcellular: cerebral cortex (UBERON:0000956), brainstem, subcortical structures; subcellular convergence on the lysosome/mTORC1 signaling hub, synaptic vesicle machinery, and ion channels.

7. Anatomical Structures Affected

• Primary organ: brain (UBERON:0000955) — cerebral cortex (UBERON:0000956), often with subcortical/brainstem network involvement.
• Body system: central nervous system (UBERON:0001017).
• Tissue/cell level: cortical gray matter; GABAergic interneurons (CL:0000617), pyramidal neurons (CL:0000598), dysmorphic neurons/balloon cells (mTORopathy), oligodendrocytes (CL:0000128; MOGHE).
• Subcellular: mTORC1 signaling complex (lysosomal surface; GO CC GO:0031931 TORC1 complex), synapse (GO:0045202), plasma-membrane ion channels.
• Localization/lateralization: generalized network dysfunction (bilateral hypsarrhythmia) but frequently arises from a focal/lateralized structural lesion (unilateral FCD, hemimegalencephaly) — a key point because focal lesions are surgically treatable. Asymmetric hypsarrhythmia suggests an underlying focal lesion.

8. Temporal Development

• Onset: infancy, typically 3–12 months (peak 4–7 months); onset >2 years is atypical. Onset pattern: subacute emergence of spasm clusters, often initially mistaken for colic, startle, or reflux — contributing to diagnostic delay.
• Course/progression: an epileptic encephalopathy — the epileptic activity itself contributes to developmental deterioration beyond the underlying etiology (ILAE DEE concept; PMID 35503712). Spasms/hypsarrhythmia often self-resolve by age 3–5 years but frequently evolve into other epilepsies (Lennox-Gastaut syndrome, focal epilepsy).
• Critical period / lead time. Time to effective treatment is prognostically decisive. In ICISS 18-month follow-up: "Increasing lead-time to treatment was associated with lower VABS scores… and worse epilepsy outcomes (p=0.023)," and "Initial control of spasms between days 14 and 42 of treatment was associated with higher mean VABS scores at 18 months (79.1 vs 63.2… p<0.001)" (O'Callaghan et al., Lancet Child Adolesc Health 2018, PMID 30236380, DOI). Smartphone video capture shortened lead time: video-captured cases were "diagnosed and started treatment 17 days earlier" with "a 25% greater response to initial standard treatment" (Rao et al., J Pediatr 2023, PMID 36931494, DOI).
• Remission: treatment-induced (hormonal/vigabatrin) is the goal; spontaneous remission of spasms occurs but with poor developmental outcome if untreated.

9. Inheritance and Population

Epidemiology. Incidence approximately 2–5 per 10,000 live births (roughly 0.25–0.42 per 1,000); prevalence in childhood on the order of 1.5–2 per 10,000. IS accounts for a large share of epilepsy with onset in the first year. (Orphanet ORPHA:3451; PMID 32827285.)

Inheritance patterns (etiology-dependent): - Autosomal dominant: TSC1/TSC2 (though ~2/3 of TSC are de novo), STXBP1, many DEE genes (usually de novo dominant). - X-linked: ARX (males affected; OMIM 308350), CDKL5. - Autosomal recessive: several metabolic causes (ALDH7A1, PNPO, biotinidase). - Chromosomal/sporadic: trisomy 21, CNVs — usually de novo. - Mosaic/somatic: brain-restricted mTOR/SLC35A2 variants (not heritable, not in blood). - Multifactorial: structural-acquired cases on a genetic background.

Penetrance/expressivity: highly variable; TSC shows near-complete penetrance but markedly variable expressivity (PMID 33892851). No genetic anticipation (except insofar as ARX polyalanine tracts). Germline mosaicism documented for TSC (recurrence risk counseling implication). Consanguinity increases recessive metabolic causes. Carrier frequency relevant for recessive metabolic forms.

Demographics: slight male predominance (~55–60%). No strong ethnic predilection overall; specific founder variants exist for particular metabolic genes in isolated populations. Geographic variation in etiology (e.g., higher perinatal-injury and infectious causes in resource-limited settings; PMID 35503712 gives guidance for resource-limited diagnosis).

10. Diagnostics

Cornerstone: EEG demonstrating hypsarrhythmia (high-amplitude, chaotic, asynchronous slow waves with multifocal spikes) — best captured on sleep/overnight or video-EEG, as hypsarrhythmia may be present only in sleep. Ictal EEG during a spasm shows the electrodecremental response. Note IESS can be diagnosed without hypsarrhythmia (PMID 35503712, 29105055).

Home video is increasingly a first diagnostic step — smartphone capture significantly shortens time to EEG, diagnosis, and treatment (Rao et al., PMID 36931494, DOI).

Neuroimaging: brain MRI (structural cause in a large fraction — tubers, FCD, HIE, malformation); may require repeat/high-resolution MRI. PET/SPECT for surgical localization of subtle lesions.

Etiologic workup: - Genetic testing: chromosomal microarray (CMA), trio whole-exome/whole-genome sequencing (highest yield), targeted epilepsy gene panels; testing of resected brain tissue for somatic/mosaic variants when blood is negative and a lesion is resected (PMID 39926610). - Metabolic screen: plasma/CSF amino acids, urine organic acids, lactate, ammonia, biotinidase, and a pyridoxine (B6) / pyridoxal-5′-phosphate trial to exclude treatable vitamin-responsive epilepsies; CSF glucose (GLUT1). - Infection: congenital CMV (urine/saliva PCR, dried blood spot), TORCH. - TSC evaluation: skin exam (Wood's lamp), echocardiogram, renal imaging, TSC1/TSC2 sequencing.

Diagnostic criteria: ILAE 2022 IESS definition (mandatory features, cautionary alerts, exclusionary features tabulated) (PMID 35503712).

Differential diagnosis: benign myoclonus of early infancy, benign infantile sleep myoclonus, Sandifer syndrome/GERD, colic, startle/hyperekplexia, tonic seizures, other early DEEs (Ohtahara syndrome, EIMFS).

11. Outcome / Prognosis

Overall. Guarded. IESS is "a devastating developmental epileptic encephalopathy" (PMID 38540325) with high rates of long-term intellectual disability, ongoing epilepsy, and autism. Prognosis is dominated by (1) etiology and (2) speed/effectiveness of spasm control.

Developmental outcome quantified. In ICISS at 18 months, mean VABS composite ~73; crucially, achieving early spasm cessation raised mean VABS from 63.2 to 79.1 (p<0.001), and freedom from seizures at 18 months was far more common in early responders (PMID 30236380, DOI).

Evolution: many progress to Lennox-Gastaut syndrome or drug-resistant focal epilepsy. Mortality is elevated relative to the general pediatric population, driven mainly by the underlying etiology and refractory epilepsy (including SUDEP risk).

Prognostic factors (better outcome): unknown/cryptogenic etiology with normal pre-onset development; short lead time to treatment; rapid and sustained response; absence of hypsarrhythmia relapse. (Worse: identified severe structural/genetic etiology, pre-existing developmental delay, long lead time, relapse.)

12. Treatment

First-line standard therapies (the NISC cohort showed first-line standard therapy is by far the strongest determinant of response — vigabatrin OR 5.2, prednisolone OR 8.0, ACTH OR 10.2; PMID 29105055, DOI):

1. Hormonal therapy — ACTH (adrenocorticotropic hormone / tetracosactide/cosyntropin depot) or oral corticosteroids (high-dose prednisolone). MAXO: MAXO:0000058/pharmacotherapy NCIT:C15986; agents — corticotropin, prednisolone (CHEBI:8382).
2. Vigabatrin (irreversible GABA-transaminase inhibitor; ↑GABA) — drug of choice for TSC-associated IS, and effective generally. Risk: irreversible peripheral visual-field constriction/retinal toxicity requiring monitoring. Vigabatrin CHEBI:63638.

Combination therapy. ICISS demonstrated hormonal + vigabatrin > hormonal alone for early spasm cessation: "no spasms were witnessed in 133 (72%) of 186 patients on hormonal therapy with vigabatrin compared with 108 (57%) of 191 patients on hormonal therapy alone (difference 15.0%… p=0.002)" (O'Callaghan et al., Lancet Neurol 2017, PMID 27838190, DOI). However, the developmental advantage did not persist at 18 months (mean VABS 73.9 vs 72.7, p=0.55) (PMID 30236380).

Comparative efficacy (meta-analysis). "There was no significant difference in the effectiveness of oral corticosteroids and ACTH… Low-dose ACTH had similar effectiveness… but conferred a lower risk of AEs… ACTH was more beneficial in controlling spasms than vigabatrin (RR = 1.31…) for patients without tuberous sclerosis complex" (Guang et al., Front Neurol 2022, PMID 35222241, DOI).

Other/second-line: ketogenic diet (MAXO: MAXO:0000010 dietary intervention / ketogenic diet); topiramate, zonisamide, valproate, pyridoxine (for B6-responsive forms), sulthiame. Epilepsy surgery — resection of a focal structural lesion (FCD, tuber, hemimegalencephaly → hemispherectomy) can be curative in lesional/mosaic cases (PMID 39926610). MAXO: surgical procedure MAXO:0000004.

Precision/targeted therapy: mTOR inhibitors (everolimus, sirolimus) for TSC-related epilepsy (mechanism-matched to mTORC1 hyperactivation); emerging gene-directed approaches for monogenic DEEs (PMID 38540325, 33892851). Everolimus (CHEBI:68478).

Treatment strategy: rapid diagnosis → prompt first-line standard therapy (hormonal ± vigabatrin; vigabatrin-first in TSC) → early EEG reassessment for response → escalate to ketogenic diet, alternative ASMs, or surgery/precision therapy if refractory. Speed matters (§8, §11).

13. Prevention

• Primary/preemptive prevention in TSC: the standout evidence — EPISTOP preventive vigabatrin (started on epileptiform EEG before clinical seizures) reduced clinical seizures, drug-resistant epilepsy, and abolished infantile spasms (OR = 0, p < 0.001) with no related adverse events (Kotulska et al., PMID 33180985, DOI). This has driven surveillance-EEG protocols in infants with known TSC.
• Secondary prevention (early detection): caregiver and pediatrician education (recognizing spasm clusters, home video), rapid-access EEG pathways to shorten lead time and improve outcomes (PMID 36931494, 30236380).
• Etiology-directed: newborn screening for treatable metabolic causes (biotinidase, PKU); congenital-infection prevention (CMV hygiene counseling, rubella vaccination).
• Genetic counseling: for TSC and monogenic DEEs — recurrence-risk assessment including germline mosaicism; prenatal/preimplantation options where a familial variant is known.
• Tertiary prevention: aggressive spasm control to limit encephalopathic developmental damage; developmental surveillance and early intervention.

14. Other Species / Natural Disease

Naturally occurring West syndrome/IESS as such is essentially a human developmental syndrome; there is no well-characterized spontaneous animal equivalent. The relevant cross-species work is in model organisms (§15). Conserved disease genes (TSC1/TSC2, ARX, mTOR pathway) have clear orthologs in mouse, rat, and zebrafish (NCBITaxon: mouse 10090, rat 10116, zebrafish 7955), enabling comparative study of mTORopathy and interneuronopathy mechanisms.

15. Model Organisms

Multiple complementary rodent models exist, each capturing part of the phenotype (reviewed by Galanopoulou, Brain Dev 2013, PMID 23312951, DOI):

• CRH-induced model — tests the stress hypothesis; CRH is more proconvulsant in developing rats, though it produces limbic (not classic flexion) seizures — a noted limitation.
• NMDA model of "emprosthotonic" (flexion) seizures, plus prenatal betamethasone and prenatal stress variants.
• γ-butyrolactone spasms in a Down syndrome (Ts65Dn) mouse model (trisomy 21 link).
• Chronic models: the tetrodotoxin (TTX) model and the "multiple-hit" rat model (structural + chronic), which reproduce spasms plus chronic epileptic and cognitive deficits and are used for drug screening.
• Genetic interneuronopathy models: ARX loss-of-function mice (polyalanine expansion / conditional knockouts) reproduce spasms via GABAergic interneuron dysfunction; TSC conditional knockouts model mTORopathy and respond to rapamycin.

The review frames these as testing distinct proposed mechanisms — "cortical or brainstem dysfunction, disruption of normal cortical-subcortical communications, genetic defects, inflammation, stress, developmental abnormalities" — and notes recent progress toward mechanism-based treatments (mTOR inhibition, carisbamate, etc.) (PMID 23312951).

Model utility & limitations: no single model reproduces the full human triad (spasms + hypsarrhythmia + developmental regression); hypsarrhythmia in particular is difficult to replicate. Models are strongest for testing etiology-specific mechanisms (mTOR, ARX/GABA, stress) and screening candidate therapies. Resources: MGI, RGD, ZFIN, IMPC/KOMP.

Summary of Key Ontology Term Suggestions

(Ontology IDs for CHEBI/GO/CL/UBERON above should be re-verified against OAK before curation, per the dismech anti-hallucination SOP; MONDO:0018097 and the HP terms HP:0012469/HP:0011097 were confirmed via OLS during this research.)

Principal References (all retrieved from PubMed)

1. Zuberi SM et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants. Epilepsia. 2022;63(6):1349-1397. PMID 35503712. DOI
2. Pavone P et al. West syndrome: a comprehensive review. Neurol Sci. 2020;41(12):3547-3562. PMID 32827285. DOI
3. Snyder HE et al. Genetic Advancements in Infantile Epileptic Spasms Syndrome and Opportunities for Precision Medicine. Genes. 2024;15(3):266. PMID 38540325. DOI
4. Islam MP. Tuberous Sclerosis Complex. Semin Pediatr Neurol. 2021;37:100875. PMID 33892851. DOI
5. Coleman M et al. The genetic landscape and classification of infantile epileptic spasms syndrome requiring surgery due to suspected focal brain malformations. Brain Commun. 2025;7(1):fcaf034. PMID 39926610. DOI
6. O'Callaghan FJK et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS). Lancet Neurol. 2017;16(1):33-42. PMID 27838190. DOI
7. O'Callaghan FJK et al. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS): 18-month outcomes. Lancet Child Adolesc Health. 2018;2(10):715-725. PMID 30236380. DOI
8. Guang S et al. Hormonal Therapy for Infantile Spasms: A Systematic Review and Meta-Analysis. Front Neurol. 2022;13:772333. PMID 35222241. DOI
9. Demarest ST et al. The impact of hypsarrhythmia on infantile spasms treatment response (National Infantile Spasms Consortium). Epilepsia. 2017;58(12):2098-2103. PMID 29105055. DOI
10. Kotulska K et al. Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial. Ann Neurol. 2021;89(2):304-314. PMID 33180985. DOI
11. Galanopoulou AS. Basic mechanisms of catastrophic epilepsy — overview from animal models. Brain Dev. 2013;35(8):748-56. PMID 23312951. DOI
12. Rao CK et al. The Effect of Smartphone Video on Lead Time to Diagnosis of Infantile Spasms. J Pediatr. 2023;258:113387. PMID 36931494. DOI

Curation notes for the dismech entry. (1) Model IESS as an etiologically heterogeneous DEE with a structural / genetic / metabolic / infectious / unknown etiology axis rather than a single mechanism. (2) The two strongest, most quotable causal chains for pathophysiology nodes are mTORopathy (TSC1/2 → mTORC1 → cortical dysplasia → spasms) and GABAergic interneuronopathy (ARX → interneuron dysfunction → E/I imbalance). (3) The lead-time-to-treatment → developmental-outcome relationship (PMID 30236380) is well-suited to a causal edge with strong human-clinical evidence. (4) Before committing any evidence item, run just fetch-reference PMID:<id> and just validate-references — the abstract quotes above are drawn verbatim from PubMed metadata but must pass the local snippet-substring check, and the CHEBI/GO/CL/UBERON IDs need OAK verification per the NEC/anti-hallucination SOP.